Blog
Featured post
Truveta Data leads a new era in cancer research
With more than 7 million oncology patient journeys spanning more than 100 cancer types, Truveta delivers an unprecedented breadth of regulatory grade data to support researchers in accelerating oncology therapy adoption and advancing critical cancer research.
Truveta Experts: Sudden cardiac arrest and arrhythmias among patients with chronic kidney disease
In this edition of Truveta Experts, Esther Kim, PhD, MPH, Senior Director of Research Services at Truveta, shares findings from her recent exploration of the burden of sudden...
Unlocking treatment insights through real-world discontinuation data
Why do patients stop taking a medication? Was it due to side effects, access barriers, or lack of efficacy? These are not just clinical questions; they’re strategic ones....
Lyme disease peaks in June, remains high through August
62.7% of Lyme cases occurred between May and August, underscoring the heightened risk during late spring and summer. June consistently showed the highest activity, accounting for...
Infection risk and adoption trends in hemodialysis catheters: New real-world evidence
Can catheter design impact patient safety? That’s the question of a new peer-reviewed study from Medical Components, Inc. (Medcomp), based on a retrospective analysis of 3,546...
GLP-1 RA prescription trends: January 2018 – June 2025
Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%). Tirzepatide is now the most...
Pediatric fluoride prescriptions fall across the US
The rate of pediatric fluoride prescriptions per all prescriptions decreased by 54.3% from the first quarter of 2022 (5.0 per 1,000 prescriptions) to the second quarter of 2025...
Truveta Experts: Real-world trends in Rituxan biosimilar adoption
In this Truveta Experts spotlight, Jared Kern and Vidya Venkataraman, PhD explored trends in the use of Rituxan biosimilars between 2018 and 2024. Their analysis of Truveta Data...
Shifting trends in initiation of disease-modifying therapies for multiple sclerosis
The proportion of patients initiating treatment for multiple sclerosis (MS) with a high efficacy disease-modifying therapy (DMT) more than doubled from 2018 to 2025, reflecting...
New AAP guidelines are changing pediatric obesity treatment—but there’s still work to do
In 2023, the American Academy of Pediatrics (AAP) released groundbreaking new guidelines recommending early treatment for childhood and adolescent obesity—including the use of...